Query our full-text historical index across market dispatches, earnings reports, central bank policies, and financial analyses.
Reporting on market developments concerning The Capitol Hill Perks That Candidates Say They Don't Deserve. Industry analysts and investors are monitoring the operational, strategic...
Alaska's unpredictable Senate contest is drawing intense scrutiny from energy markets and institutional strategists as Capitol Hill's legislative balance hangs in the balance.
Eli Lilly posted robust quarterly financial results driven by flagship injectables, though clinical nuances in its oral obesity pipeline tempered investor enthusiasm.
U.S. mortgage rates retreated for a second straight week, offering cautious optimism to prospective homebuyers amid declining Treasury yields.
Political maneuvering in Alaska's critical congressional contest highlights high-stakes battles over federal land management, resource permitting, and the national energy agenda.
As debates over the European Central Bank's next presidency gain traction, financial markets are evaluating the future path of Eurozone rate strategy and economic stability.
Eli Lilly posted significant revenue gains driven by unprecedented global demand for its blockbuster treatments Mounjaro and Zepbound, solidifying its leadership in the metabolic therapeutics market.
In an unusual operational pivot, AI-driven biotech Formation Bio has raised its own investment fund to acquire and advance clinical-stage drug candidates.
A contentious gubernatorial battle pitting a municipal veteran against a billionaire industrialist creates sharp policy contrasts for corporate investment and state fiscal strategy.
Demographic realignments in Texas are altering the political calculus, with major implications for energy policy, corporate relocations, and fiscal outlooks.
Former Fed Governor Kevin Warsh has opted out of a White House hearing involving Governor Lisa Cook, underscoring ongoing tensions over monetary policy oversight.
Moderna Chief Executive Stéphane Bancel remains steadfast on the company's individualized cancer vaccine program despite recent equity selloffs and shifting market expectations.